Tirabrutinib hydrochloride for B-cell lymphomas.

Area of Science:

• Oncology
• Pharmacology
• Immunology

Background:

• Bruton tyrosine kinase (BTK) is crucial in B-cell receptor signaling, making it a key target for B-cell malignancies.
• Ibrutinib, a first-in-class BTK inhibitor, is approved for several B-cell cancers but has off-target effects.
• There is a need for more specific BTK inhibitors to overcome ibrutinib's limitations.

Purpose of the Study:

• To provide a comprehensive review of the preclinical and clinical activity of tirabrutinib hydrochloride (tirabrutinib).
• To evaluate tirabrutinib as a potent, selective, irreversible BTK inhibitor for B-cell malignancies.

Main Methods:

• Review of preclinical data including in vitro cytotoxicity and in vivo antitumor activity in mouse models.
• Analysis of clinical trial data for tirabrutinib in patients with B-cell malignancies.
• Assessment of tirabrutinib's selectivity and mechanism of action as an irreversible BTK inhibitor.

Main Results:

• Tirabrutinib demonstrates potent, highly selective, and irreversible inhibition of BTK.
• Effective in vitro cytotoxicity and in vivo antitumor activity were observed in various B-cell malignancies.
• Tirabrutinib is approved in Japan for relapsed/refractory primary CNS lymphoma and Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.

Conclusions:

• Tirabrutinib represents a promising, selective BTK inhibitor for treating B-cell malignancies.
• Its efficacy in specific hematological cancers warrants further clinical investigation.
• Tirabrutinib addresses the need for targeted therapies with potentially improved safety profiles compared to less selective inhibitors.